IGC Pharma, Inc. has announced the achievement of a 50% patient enrollment milestone in its Phase 2 CALMA clinical trial, which is focused on evaluating IGC-AD1 for treating agitation in Alzheimer's disease. This trial is a multicenter, double-blind, placebo-controlled, and randomized study. The company has expanded its geographic reach and enhanced patient diversity by adding new sites in Florida, Ontario, Rhode Island, Oklahoma, British Columbia, and Puerto Rico. The trial aims to complete recruitment by 2026. IGC-AD1, the company's proprietary formulation, combines low concentrations of delta-9 tetrahydrocannabinol $(THC)$ with another active pharmaceutical ingredient, targeting both agitation and potential disease-modifying effects in Alzheimer's patients. Results from the trial, which builds on promising Phase 1 and interim Phase 2 data, are expected to be fully analyzed upon trial completion in early 2026.